Has John Costouros, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,494,226 in general payments to John Costouros, MD across 539 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Costouros, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Costouros, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Costouros, MD

Orthopaedic Surgery · Redwood City, CANPI 1437238565

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $1,060,252 of the $1,494,226 with a category attached, or 71.0%. 18 manufacturers reported payments, led by Arthrex at 47.5% of the total. Reporting peaked in 2022 at $447,399 and has fallen 74.0% since, to $116,298 in 2025. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,494,226in general payments, 2019–2025

Across 539 payments — averaging $2772.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arthrex$710K
Stryker$529K
Medacta USA, Inc.$124K
Catalyst Orthoscience$77K
FX Shoulder Solutions, Inc$29K
Shoulder Innovations, Inc.$16K
plus $9K from 12 others

$137,640in research payments, 2019–2025

Across 7 payments — averaging $19,663 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

FX Shoulder Solutions, Inc$134K
Zimmer Biomet$2K
Stryker$715

$20,988in ownership & investment interests, 2019–2025

Across 5 payments — averaging $4197.55 each. An ownership or investment interest held by the physician or an immediate family member.

Catalyst Orthoscience$21K

What the payments were for

Royalty or licence$1,060,25271%
Consulting fees$300,59120%
Speaking & faculty fees$29,7052%
Travel & lodging$85,6796%
Food & beverage$17,9391%
Gifts$590%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arthrex	53	$709,824
Stryker(2 entities)	319	$528,684
Medacta USA, Inc.	84	$123,765
Catalyst Orthoscience	10	$77,388
FX Shoulder Solutions, Inc	8	$29,477
Shoulder Innovations, Inc.	27	$16,409
Depuy Synthes Products, Inc.	3	$2,925
Acelrx Pharmaceuticals, Inc.	1	$2,000
Evolution Surgical, Inc	12	$1,828
Zimmer Biomet	9	$1,048
Hikma Pharmaceuticals USA	1	$344
Johnson & Johnson(2 entities)	4	$182
Biedermann Motech, Inc.	1	$101
Smith+Nephew	1	$94
Pacira Pharmaceuticals Incorporated	2	$67
Heron Therapeutics, Inc.	2	$44
Medical Device Business Services, Inc.	1	$27
Kinamed, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ARTHREX$2,230,283
AEQUALIS PERFORM$300,008
ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE REVERS$186,744
BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION$94,390
Catalyst Total CSR$73,976
ARTHROPLASTY IMPLANTS REVERS TOTAL SHOULDER REVERS$62,945
AEQUALIS ASCEND FLEX$55,768
SIMPLICITI$43,262
Shoulder System$39,062
TORNIER PERFORM ANATOMIC AUGMENTED GLENOID$36,112
TORNIER PERFORM REVERSED AUGMENTED GLENOID$36,112
PRIMARY SHOULDER$33,353
TORNIER PERFORM REVERSED GLENOID$32,306
REUNION$21,755
NEXTAR$21,587
AEQUALIS PERFORM REVERSED$20,213
BLUEPRINT PSI SYSTEM$18,854
InSet System$16,006
T2$14,438
AXSOS$14,438

How this compares

$1,494,226 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.

See all orthopaedic surgery providers in California →

Medicare billing

Part B allowed, 2024

$446,396

Medicare patients

449

Services billed

2,179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amoxicillin	16	$44

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Redwood City

Bradford HackArcadia$18.3M
Robert GorabOrange$13.6M
Kelly VinceLos Angeles$9.6M
Stephen HowellSacramento$9.4M
Thomas CoonRed Bluff$9.2M
Nirav AminPlacentia$5.6M
Tom NorrisSan Francisco$5.3M
Jay LiebermanLos Angeles$4.8M
Peter NewtonSan Diego$4.2M
Sigurd BervenSan Francisco$4.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →